A prospective randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors

#3332

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Aim(s): The purpose of this study is to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors.

Materials and methods: Patients were equally randomized into two arms: Arm A, 68Ga-NODAGA-LM3; Arm B, 68Ga-DOTA-LM3. Serial PET scans were acquired at 5, 15, 30, 45, 60, and 120 minutes after 68Ga-NODAGA-LM3 or 68Ga-DOTA-LM3 injection. The biodistribution in normal organs, tumor uptake, and safety was assessed. Radiation dosimetry was calculated using OLINDA/EXM 1.0.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Cheng Y, Jia R, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, neuroendocrine tumor,